The full content of Annals is available to subscribers

Subscribe/Learn More  >
Letters |

Inhaled Long-Acting β-Agonists Versus Anticholinergics in Older Patients With Chronic Obstructive Pulmonary Disease

Leonardo M. Fabbri, MD; Claus Vogelmeier, MD; and Klaus F. Rabe, MD
[+] Article, Author, and Disclosure Information

From University of Modena and Reggio Emilia, 41124 Modena, Italy; Hospital of the Universities of Giessen and Marburg, 35043 Marburg, Germany; and Hospital Grosshansdorf, 22927 Grosshansdorf, Germany.

Potential Conflicts of Interest: Dr. Fabbri has received consultancy fees from Actelion, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Elevation Pharmaceuticals, Merck Sharp & Dohme, Novartis, Nycomed, Pearl Therapeutics, Roche, and Sigma-Tau and payment for lectures and support for travel expenses from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, EUROMEDIFORM, GlaxoSmithKline, German Centre for Lung Research, Merck Sharp & Dohme, Menarini, Mundipharma International, Novartis, Nycomed, TEVA Pharmaceuticals, Pfizer, and Sigma-Tau. His institution has received grants from Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Italian Ministry of Health, Italian Ministry for University and Research, Merck Sharp & Dohme, Nycomed, and Sigma-Tau. Dr. Vogelmeier has received consulting fees or honoraria and support for travel to meetings from Boehringer Ingelheim; is a board member for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Novartis, and Nycomed; and has received fees for expert testimony and grants from Talecris and payment for lectures or speaking from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Nycomed, and Talecris. Dr. Rabe has received consultancy fees and honoraria from, and is a board member for, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, and Pfizer and has received grants from Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche.

Ann Intern Med. 2011;155(8):561. doi:10.7326/0003-4819-155-8-201110180-00018
Text Size: A A A





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.